Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Targets 18 Drug Launches From 2012 To 2015

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.

Advertisement

Related Content

Teva’s Generic Irbesartan Deserves 180-Day Exclusivity Because Of Review Delays, FDA Says
More Insulin Innovation To Come, Says Novo CEO Sorensen
After The Patent Cliff, "New" Sanofi Will Deliver Steady, Modest, Growth
Apotex To Retain About $300 Million From Its At-Risk Launch of Generic Plavix

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel